Nanobiotix drops 12% on Nasdaq following FDA announcement
Nanobiotix shares fall 12% on Nasdaq with significant trading volumes.
Published 14sem1 sourceImportantupdated 3j
Lire en français
≈ 15s
The fact
The FDA announcement regarding head and neck treatments triggered this correction.
The immediate market reaction suggests disappointment about therapeutic prospects.
Click the link to read an article on the topic: